NRIX: Bull Flag detected on 26 Jun 2026

NRIX is forming a bull flag following a three-white-soldiers pattern established June 23. At $22.46, price sits near the 52-week high (down only 2.73%), having rallied 31.19% in one week and 46.8% in two weeks. Structure scores 14.6/15, volume scores 12.0/12 (6M shares at 1.73x average), and breakout scores 10.0/13. The pattern scores 81.6 overall with a 72.58% win probability. Key resistance sits at $18.91; key support at $16.50. The conservative target is $23.20. RSI at 81.15 signals extreme overbought conditions.

On June 8, 2026, Nurix announced a global collaboration with Roche valued at $700M upfront with up to $2.3B in milestones to co-develop bexobrutideg, a BTK degrader for cancer, immunology, and neurology. On June 11, Nurix reported Phase 1a/1b CLL data showing 83% overall response rate and 22.1-month progression-free survival in heavily pretreated patients. Baird raised its price target to $33 from $26 on June 18, and multiple analysts maintained Buy ratings post-data release. The company has $83.98M in annual revenue, operating losses of ~$92.5M, but maintains a strong balance sheet with $540.7M in cash and short-term investments. The Roche deal and positive clinical readouts are driving the sharp two-week rally.

A successful bull flag breakout above $18.91 resistance would confirm the pattern, targeting the conservative measure at $23.20—representing minimal upside from current price. The pattern's 72.58% historical win rate suggests favorable odds, though the measured move is modest. Volume confirmation is strong at 1.73x average. Invalidation occurs below $16.50 support, which would negate the bull flag structure. Given the extreme 81.15 RSI reading, additional momentum may be constrained near-term even on breakout.

Critical overbought conditions: RSI at 81.15 indicates extreme exhaustion and heightened pullback risk. Execution risks center on clinical and regulatory outcomes for bexobrutideg, and Nurix's ability to fund its 40% share of development without further dilution. The Roche transaction remains subject to antitrust clearance, introducing deal closure uncertainty. Nurix is unprofitable with widening losses, has diluted shareholders, and trades on a rich sales multiple. The $700M upfront is not yet received; clinical trial failures in the DAYBreak pivotal program would catastrophically undermine the valuation thesis. High beta of 1.12 and 84.87% 20-day volatility compound downside risk if sentiment reverses.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.